This preview shows pages 1–3. Sign up to view the full content.
This preview has intentionally blurred sections. Sign up to view the full version.View Full Document
Unformatted text preview: Subscriber access provided by University of Florida | Smathers Libraries ACS Nano is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Article Targeting of Porous Hybrid Silica Nanoparticles to Cancer Cells Jessica M. Rosenholm, Annika Meinander, Emilia Peuhu, Rasmus Niemi, John E. Eriksson, Cecilia Sahlgren, and Mika Linde#n ACS Nano , 2009 , 3 (1), 197-206 DOI: 10.1021/nn800781r Publication Date (Web): 23 December 2008 Downloaded from http://pubs.acs.org on April 7, 2009 More About This Article Additional resources and features associated with this article are available within the HTML version: Supporting Information Access to high resolution figures Links to articles and content related to this article Copyright permission to reproduce figures and/or text from this article Targeting of Porous Hybrid Silica Nanoparticles to Cancer Cells Jessica M. Rosenholm, Annika Meinander, ,, ' , Emilia Peuhu, ,, Rasmus Niemi, John E. Eriksson, , Cecilia Sahlgren, ,, * and Mika Linde n , * Center for Functional Materials, Department of Physical Chemistry, bo Akademi University, Porthansgatan 3-5, FI-2500 Turku, Finland, Department of Biology, bo Akademi University, Artillerigatan 6A, FI-20520 Turku, Turku Centre for Biotechnology, University of Turku and bo Akademi University, P.O. Box 123, FI-20521, Turku, Finland, and ' Current address: The Breakthrough Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London SW3 6JB, United Kingdom. Both authors contributed equally to this work. T argeting and drug delivery to spe- cific cell populations are key aims in biomedical science today. Research efforts are, therefore, being placed on gen- erating drug delivery systems to specifically target drugs to malfunctioning cells. Cellu- lar targeting by utilizing antibodies or spe- cific ligands rely on the capability of the tar- geting agents to selectively bind to the cell surface to trigger receptor-mediated en- docytosis. 1 The drug delivery system along with the therapeutic agent would thereby be delivered to the interior of a given type of cells. Such a drug delivery system will not only have important therapeutic and phar- macological applications but also be of great interest for medical imaging and diag- nosis. Targeting is especially relevant in the context of cancer therapies, as most of the commonly used anticancer drugs have seri- ous side-effects due to unspecific action on healthy cells. The selectivity is a function of the ability of the nanoparticles to be inter- nalized by the targeted cell population. But at least as important for the biological activ- ity is the efficiency of uptake, that is, num- ber of nanoparticles internalized by cancer cells in comparison to nontarget cells, as drug concentration is a key parameter for successful treatment....
View Full Document
- Spring '08